Harnessing natural compounds to modulate miRNAs in breast cancer therapy

Shaza H Aly1, Ahmed I Abulsoud2,3, Yasser M Moustafa4

  • 1Department of Pharmacognosy, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo, 11829, Egypt.

PubMed

Insights

MicroRNAs (miRNAs) play a dual role in breast cancer, acting as oncogenes or tumor suppressors. Natural compounds can modulate miRNA expression, offering new targeted therapies for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer is complex and heterogeneous, posing treatment challenges.
  • MicroRNAs (miRNAs) are key regulators of gene expression in breast cancer pathogenesis.
  • miRNAs exhibit dual roles as oncogenes and tumor suppressors.

Purpose of the Study:

  • To review the role of miRNAs in breast cancer.
  • To explore miRNA mechanisms, therapeutic strategies, and natural compound interactions.
  • To highlight novel miRNA- and natural product-based therapeutic approaches.

Main Methods:

  • Literature review of current research on miRNAs in breast cancer.
  • Analysis of miRNA functions (oncogenic/tumor suppressive) and biological impacts (proliferation, apoptosis, metastasis).
  • Exploration of miRNA-mRNA interactions and regulatory factors.

Main Results:

  • miRNAs significantly influence cell proliferation, apoptosis, and metastasis in breast cancer.
  • Nanoparticle delivery systems enhance miRNA-based therapy stability and efficacy.
  • Natural compounds (e.g., genistein, curcumin, EGCG) modulate miRNA expression and inhibit tumor growth.

Conclusions:

  • miRNAs are critical regulators with therapeutic potential in breast cancer.
  • Targeted miRNA-based therapies, including nanoparticle delivery, show promise.
  • Natural compounds offer complementary strategies by modulating miRNA expression for enhanced breast cancer treatment.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K